Femoroacetabular Impingement RandomiSed Controlled Trial (FIRST); Sub-study: Femoroacetabular Impingement RandomiSed Controlled Trial With an Embedded Prospective Cohort (FIRST-EPIC)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- McMaster University
- Enrollment
- 220
- Locations
- 10
- Primary Endpoint
- Pain (measured using a Visual Analog Scale)
Study Overview
Brief Summary
The purpose of this study is to determine whether surgical correction of hip impingement morphology via arthroscopic osteochondroplasty (shaving of bone) will provide improved clinical results (decreased pain and improved function) in adult patients with femoroacetabular impingement (FAI) compared to arthroscopic lavage (washing out of painful inflammation debris) and treating obvious damage of the hip joint.
Detailed Description
Femoroacetabular impingement (FAI) is a condition of the hip where there is a mismatch of the ball and socket in the hip joint. This mismatch creates abnormal contact in the hip which can cause patients to experience hip pain. This can eventually lead to hip damage and osteoarthritis. Hip arthroscopy, a form of minimally invasive surgery has become a popular treatment option. The investigators are conducting a definitive randomized controlled trial (RCT) to determine whether surgical correction of the impingement morphology via arthroscopic osteochondroplasty (shaving of bone) will provide improved clinical results (decreased pain and improved function) in adult FAI patients compared to arthroscopic lavage (washing out of painful inflammation debris) and treating obvious damage of the hip joint.
Like most RCTs, FIRST is designed to demonstrate efficacy (i.e. that an intervention can work theoretically under optimal conditions). In order to address generalizability and improve external validity of the FIRST trial, we are including an external validation cohort using a "RCT with and Embedded ProspectIve Cohort design" (FIRST-EPIC). This pragmatic cohort will allow us to: 1) safeguard against bias attributable to patients declining to take part in the RCT; 2) corroborate or refute whether our efficacy (RCT) population represents the best case scenario (i.e. those with optimal response to osteochondroplasty); 3) evaluate effectiveness of osteochondroplasty and other standard of care treatments for FAI in patients with potentially distinct prognostic factors; and 4) evaluate the cost-effectiveness of the interventions.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult men or women ages 18 to 50 years
- •Hip pain for greater than 6 months with no relief from non-operative means (physiotherapy, non-steroidal anti-inflammatory medication, rest)
- •Documentation of failed physiotherapy, including core conditioning of the hip, back, and abdomen
- •CAM or Mixed Type FAI as diagnosed on x-rays and magnetic resonance imaging (MRI) or magnetic resonance arthrogram (MRA)
- •Temporary relief from an intra-articular hip injection
- •Informed consent from participant
- •Ability to speak, understand and read in the language of the clinical site
Exclusion Criteria
- •Previous inclusion in a study involving FAI
- •Evidence of hip dysplasia (centre edge angle less than 20)
- •Presence of advanced hip osteoarthritis (Tonnis Grade 2 or 3)
- •Presence of other hip syndromes (concurrent non-FAI related pathology)
- •Previous trauma to the affected hip
- •Previous surgery on the affected hip or contralateral hip
- •Severe acetabular deformities (e.g. acetabular protrusion, coxa profunda, circumferential labral ossification)
- •Immunosuppressive medication use
- •Chronic pain syndromes
- •Significant medical co-morbidities (requiring daily assistance for ADLs)
- •History of paediatric hip disease (Legg-Calve-Perthes; slipped capital femoral epiphysis)
- •Ongoing litigation or compensation claims secondary to hip problems
- •Any other reasons given to exclude the patient
- •If a patient does not meet the eligibility criteria for the FIRST trial, they may be considered eligible for the FIRST-EPIC sub-study.
Arms & Interventions
Arthroscopic Lavage
Participants have three hip portals (antero-lateral, mid anterior, distal antero-lateral) with limited capsulotomy allowing for a complete assessment of the central and peripheral compartments. The participant has a diagnostic arthroscopy and lavage of the hip joint with three litres of normal saline. No osteochondroplasty or rim resection is completed in this group. No instruments are used to treat minor cartilage or labral damage. The labrum should only be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The labrum will be refixated only if the above criteria for labral instability is met.
Intervention: Arthroscopic Lavage (Procedure)
Arthroscopic Osteochondroplasty
After establishing standard portals, an inter-portal capsulotomy will be completed to allow for complete evaluation of the central compartment of the hip. Significant and obvious labral tears and cartilage damage will be addressed. The labrum will be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The acetabular rim will be evaluated and any evident Pincer lesion will be resected using an arthroscopic burr under fluoroscopic guidance. Following this resection, the labrum will be refixated only if the criteria for labral instability is met. Following this, a limited capsulotomy will be completed along the head-neck junction of the femoral neck to allow for visualization and treatment of the impingement lesion in the peripheral compartment. For the FIRST-EPIC sub-study, participants will receive the osteochondroplasty intervention as per standard of care.
Intervention: Arthroscopic Osteochondroplasty (Procedure)
Outcomes
Primary Outcomes
Pain (measured using a Visual Analog Scale)
Time Frame: 12 months
The VAS is one of the most frequently used pain rating scales in clinical practice and research. The VAS is a validated unidimensional scale that is easy to use, requires no verbal or reading skills, and is sufficiently versatile to be employed in a variety of settings. The VAS will be administered during routine follow up visits at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.
Secondary Outcomes
- Complications / Adverse events(12 and 24 months)
- Function and lifestyle (measured using the International Hip Outcome Tool)(12 months)
- Health utility (measured using the Euro-Quol 5 Dimensions)(12 months)
- Urinary function (measured using the Male/Female Lower Urinary Tract Symptoms questionnaires)(12 months)
- Health-related quality of life (measured using the Short-Form 12)(12 months)
- Function (measured using the Hip Outcome Score)(12 months)
- Sexual function (measured using the International Index of Erectile Dysfunction and the Female Sexual Function Index)(12 months)